In the article by Docherty et al, “Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction” which appears in the July 20, 2021, issue of the journal (Circulation. 2021;144:199–209. DOI: 10.1161/CIRCULATIONAHA.121.054892), corrections are needed. The lower bound of the 95% confidence interval was incorrectly published as –4.9 instead of –4.8.

In the results section of the abstract, the confidence interval in the following sentence was updated:

Sacubitril/valsartan, compared with valsartan, did not significantly reduce LV end-systolic volume index; adjusted between-group difference, –1.9 mL/m2 (95% CI, –4.8 to 1.0); P=0.19.

On page 202, the confidence interval in the following sentence was updated:

LVESVI decreased by 4.0±6.6 mL/m2 between baseline and 52 weeks in the sacubitril/valsartan group and by 2.0±7.3 mL/m2 in the valsartan group: adjusted between-group difference, –1.9 (95% CI, –4.8 to 1.0) mL/m2; P=0.19 (Table 2 and Figure 1).

Also, in the row for LVESVI in Table 2, the entry for Between group difference (95% CI) was updated to –1.9 (–4.8, 1.0).

The correction has been made to the current online version of the article, which is available at https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054892.

在 Docherty 等人发表于 2021 年 7 月 20 日期刊（循环.2021；144）的文章中，“脑啡肽酶抑制对心肌梗死后晚期无症状左心室收缩功能障碍患者左心室重构的影响” ： 199–209. DOI: 10.1161/CIRCULATIONAHA.121.054892)，需要更正。95% 置信区间的下限被错误地发布为 –4.9 而不是 –4.8。

在摘要的结果部分，更新了以下句子中的置信区间：

与缬沙坦相比，沙库巴曲/缬沙坦并没有显着降低 LV 收缩末期容积指数；调整后的组间差异，–1.9 mL/m2（95% CI，–4.8 至 1.0）；P = 0.19。

在第 202 页上，更新了以下句子中的置信区间：

沙库巴曲/缬沙坦组 LVESVI 在基线和 52 周之间下降 4.0±6.6 mL/m2，缬沙坦组下降 2.0±7.3 mL/m2：调整组间差异，–1.9（95% CI，–4.8 至 1.0 ) 毫升/平方米；P = 0.19（表 2 和图 1）。

此外，在表 2 中 LVESVI 的行中，组间差异 (95% CI) 的条目更新为 –1.9 (–4.8, 1.0)。

已对文章的当前在线版本进行更正，该版本可在 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054892 上获得。